Mounjaro vs Zepbound: Same Drug, Different Labels Explained

How They Work

Mounjaro and Zepbound are the same drug. Both contain tirzepatide, a synthetic dual-action hormone manufactured by Eli Lilly and Company. Both are injected once per week using a prefilled pen device. The molecule inside each pen is identical. There is no chemical, pharmacological, or structural difference between the tirzepatide in a Mounjaro pen and the tirzepatide in a Zepbound pen.

Tirzepatide is a dual GLP-1/GIP receptor agonist. It simultaneously activates two incretin hormone pathways your body uses naturally to regulate appetite, blood sugar, and energy metabolism. Most competing medications in this class, including semaglutide (Ozempic, Wegovy), target only GLP-1. Tirzepatide targets both GLP-1 and GIP.

GLP-1 (glucagon-like peptide-1) is a hormone released by cells in your gut after eating. It tells your pancreas to produce insulin, signals your brain that you have eaten enough, and slows gastric emptying so food stays in your stomach longer. These effects reduce appetite and stabilize blood sugar simultaneously.

GIP (glucose-dependent insulinotropic polypeptide) is the other major incretin hormone and actually the dominant one in healthy humans. Your body releases more GIP than GLP-1 after a meal. GIP receptors are found in the pancreas, fat tissue, brain, and bone. Activating GIP receptors enhances insulin sensitivity, improves fat oxidation (your body's ability to burn stored fat for fuel), and amplifies the appetite-suppressing effects of GLP-1 through brain signaling. The dual mechanism is what separates tirzepatide from every pure GLP-1 agonist on the market.

Natural incretin hormones break down in the body within minutes. Tirzepatide was engineered to resist that degradation. Eli Lilly modified the molecule to extend its half-life to approximately five days, making once-weekly dosing effective. A single injection maintains steady activation of both receptor systems for a full seven days.

Both products use the same dose range: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. Both use the same titration schedule. Both use the same injection device. If you took the tirzepatide out of a Mounjaro pen and the tirzepatide out of a Zepbound pen at the same dose strength and ran them through mass spectrometry, the readouts would be indistinguishable.

So why do two brand names exist? Because the FDA approved them for different medical conditions. Mounjaro received approval in May 2022 for adults with Type 2 diabetes. Its clinical trial program, called SURPASS, was designed to demonstrate blood sugar reduction measured by HbA1c. Zepbound received approval in November 2023 for chronic weight management in adults with a BMI of 30 or higher (obesity), or 27 or higher with at least one weight-related comorbidity. Its trial program, called SURMOUNT, measured weight loss as the primary endpoint.

These are separate FDA approvals with separate New Drug Application numbers, separate National Drug Codes, and separate labeling. The FDA treats Mounjaro and Zepbound as distinct products despite containing the same active ingredient. Eli Lilly used the same regulatory playbook Novo Nordisk used when it launched semaglutide as both Ozempic (diabetes) and Wegovy (obesity). One molecule, two indications, two commercial products.

The dose ranges are identical across both labels. Both start at 2.5 mg for the first four weeks as a sub-therapeutic introductory dose designed to reduce gastrointestinal side effects. After four weeks, the dose increases to 5 mg. From there, a prescriber can escalate in 2.5 mg increments every four weeks up to the maximum of 15 mg. The titration schedule, the pen devices, and the injection technique are the same. A pharmacist dispensing Mounjaro 10 mg and a pharmacist dispensing Zepbound 10 mg are handing patients the exact same amount of the exact same molecule in the exact same type of device.

What the Research Shows

The clinical evidence behind tirzepatide comes from two major trial programs. SURPASS tested it in people with Type 2 diabetes. SURMOUNT tested it in people with obesity. Both produced strong results across multiple large, randomized, placebo-controlled trials.

The SURPASS program is the foundation of Mounjaro's FDA approval. SURPASS-1 through SURPASS-5 enrolled adults with Type 2 diabetes and measured HbA1c reduction as the primary endpoint, with weight loss tracked secondarily. The most important of these was SURPASS-2, published in the New England Journal of Medicine (PMID: 34170647). It compared tirzepatide head-to-head against semaglutide 1 mg in 1,879 adults with Type 2 diabetes over 40 weeks. Tirzepatide was superior at all three dose levels (5 mg, 10 mg, and 15 mg) for both HbA1c reduction and weight loss. At 15 mg, tirzepatide reduced HbA1c by 2.3 percentage points compared to 1.86 for semaglutide. Weight loss in the SURPASS program ranged from 5 kg to 12 kg depending on dose and trial duration. These numbers are lower than the SURMOUNT results because people with Type 2 diabetes consistently lose less weight on incretin medications than people without diabetes, likely due to the effects of insulin resistance and diabetes medications on body weight regulation.

The SURMOUNT program is the foundation of Zepbound's FDA approval. SURMOUNT-1, published in the New England Journal of Medicine in 2022 (PMID: 35658024), enrolled 2,539 adults with obesity or overweight (without diabetes). At 72 weeks, average weight loss was 15.0% at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg. More than one-third of participants on the 15 mg dose lost over 25% of their body weight. At the time of publication, these were the largest weight reductions ever recorded in an obesity pharmacotherapy trial.

SURMOUNT-2 studied tirzepatide in adults with both obesity and Type 2 diabetes (PMID: 37385275). Even in this harder-to-treat population, the 15 mg dose produced 14.7% weight loss at 72 weeks, along with substantial improvements in glycemic control. SURMOUNT-3 combined tirzepatide with an intensive 12-week lifestyle intervention (calorie restriction and increased physical activity) before randomization. Participants who continued tirzepatide after the lead-in period lost an additional 18.4% of body weight by week 72. SURMOUNT-4 used a withdrawal design: all participants received tirzepatide for 36 weeks, then half switched to placebo (PMID: 38078870). Those who continued lost 21.4% total body weight. Those who stopped regained approximately half of their lost weight over the following year, confirming that tirzepatide must be taken continuously to maintain its effects.

The most recent and arguably most consequential trial is SURMOUNT-5, the first head-to-head comparison of tirzepatide against semaglutide for weight loss (PMID: 39652484). Published in the New England Journal of Medicine, it enrolled 751 adults with obesity and randomized them to tirzepatide (up to 15 mg) or semaglutide (up to 2.4 mg) for 72 weeks. Tirzepatide produced 20.2% weight loss versus 13.7% for semaglutide. The difference was statistically significant (p<0.001). This trial established tirzepatide as the more effective molecule for weight reduction when both drugs are dosed at their maximum approved levels.

One notable gap in the data: tirzepatide does not yet have a completed large-scale cardiovascular outcomes trial. The SURPASS-CVOT trial is underway and will evaluate whether tirzepatide reduces major cardiovascular events (heart attack, stroke, cardiovascular death). Results have not been published as of early 2026. Until that data is available, semaglutide (Wegovy) holds a unique position as the only incretin-based medication with a completed cardiovascular mortality benefit trial (the SELECT trial, PMID: 37952131). For patients with established cardiovascular disease, this distinction is clinically relevant.

Side Effects and Tolerability

The side effect profile is the same for Mounjaro and Zepbound because they are the same drug. Adverse event data from both the SURPASS and SURMOUNT trial programs applies equally to both products.

Gastrointestinal effects are the most common. Nausea, diarrhea, vomiting, constipation, and abdominal discomfort dominate the side effect profile, particularly during dose escalation. In SURMOUNT-1 (PMID: 35658024), nausea occurred in 24.6% of participants at 5 mg, 33.3% at 10 mg, and 31.0% at 15 mg. Diarrhea rates ranged from 17% to 21%. Vomiting occurred in 8% to 12%. Constipation affected 11% to 17%. Most symptoms were mild to moderate, peaked during the first few weeks at each new dose level, and resolved with continued use at a stable dose.

These GI rates are notably lower than those reported for semaglutide at the 2.4 mg dose. In the STEP 1 trial (PMID: 33567185), nausea affected 44% and vomiting affected 25% of participants on semaglutide. The dual GIP/GLP-1 mechanism likely contributes to tirzepatide's better GI tolerability. GIP receptor activation appears to partially buffer the gastrointestinal effects caused by GLP-1 agonism, producing greater appetite suppression with proportionally less nausea.

Injection site reactions occurred in approximately 3-5% of participants. These were generally mild, consisting of redness, itching, or minor discomfort.

Gallbladder-related events, including gallstones (cholelithiasis) and gallbladder inflammation (cholecystitis), have been observed in clinical trials of both tirzepatide and semaglutide. Rapid weight loss from any cause increases gallstone risk because the liver excretes more cholesterol into bile during caloric deficit. This is not unique to tirzepatide. It is a known consequence of significant weight loss achieved through medication, surgery, or intensive dieting.

Cases of acute pancreatitis have been reported at low rates in clinical trials and post-marketing surveillance. The incidence was approximately 0.2% in the SURMOUNT program. All GLP-1-based medications carry a label warning about pancreatitis risk. Patients who develop severe, persistent abdominal pain should seek medical evaluation and discontinue the medication if pancreatitis is confirmed.

Tirzepatide also carries a boxed warning about the risk of thyroid C-cell tumors based on findings in rodent studies. GLP-1 receptor agonists caused dose-dependent thyroid C-cell tumors in rats and mice. Whether this finding translates to humans is unknown. Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

The single most important factor in managing side effects is following the prescribed titration schedule. The standard escalation starts at 2.5 mg for four weeks, then increases by 2.5 mg every four weeks up to the target dose. This gradual ramp gives the body time to adapt. Patients who skip dose levels or accelerate the titration experience significantly more nausea and vomiting. Not everyone needs to reach 15 mg. Many patients achieve effective results at 10 mg or 12.5 mg with fewer side effects.

Cost, Access, and Practical Considerations

For most patients, the choice between Mounjaro and Zepbound comes down to insurance coverage. The drug is the same. The dose is the same. What differs is how your insurer classifies the claim and whether they will pay for it.

Mounjaro processes through the diabetes drug benefit. Most commercial insurance plans, Medicare Part D, and Medicaid programs have established formulary positions for diabetes medications. If you have a documented Type 2 diabetes diagnosis, getting Mounjaro approved is generally predictable. Some plans require prior authorization. Some impose step therapy, meaning you must try metformin or another first-line drug before the insurer will approve tirzepatide. But the pathway is well-established and widely understood by prescribers and pharmacies.

Zepbound processes through the obesity or weight management benefit, which is a different landscape entirely. For decades, many insurance plans explicitly excluded anti-obesity medications from their formularies. That picture has been shifting since 2023 as clinical trial data demonstrated medically significant weight loss with metabolic benefits. Several major commercial insurers have expanded coverage for FDA-approved anti-obesity medications. But coverage remains inconsistent. Some plans cover Zepbound with standard prior authorization. Some require documented failure of structured diet and exercise programs lasting six months or longer. Some require a BMI above 35 rather than the FDA-approved threshold of 30. Some limit coverage to patients with specific comorbidities. Some require the prescriber to be an obesity medicine specialist. And some plans still exclude anti-obesity drugs entirely. The only way to know your specific coverage is to have your prescriber submit the claim and see what comes back.

Medicare is a notable gap. As of early 2026, Medicare Part D does not cover anti-obesity medications. The Treat and Reduce Obesity Act, which would change this, has been introduced in Congress multiple times but has not been enacted. Medicare beneficiaries can access Mounjaro if they have Type 2 diabetes, but Zepbound for weight management is not covered under traditional Medicare. Some Medicare Advantage plans offer supplemental coverage that includes weight management drugs, but this varies by plan and region.

Without insurance, both drugs carry significant costs. Mounjaro has a wholesale acquisition cost of approximately $1,023 per month. Zepbound lists at approximately $1,060 per month. Eli Lilly offers manufacturer savings programs for commercially insured patients that can reduce out-of-pocket costs to $25-$50 per month for eligible individuals. The LillyDirect program and associated savings cards are the primary vehicles for these discounts. These manufacturer programs typically do not apply to patients on government insurance (Medicare, Medicaid, Tricare) or those without any insurance.

Off-label Mounjaro prescribing for weight loss is common and legal. Physicians can prescribe any FDA-approved medication for any condition they judge clinically appropriate. The advantage is that the prescription processes through the diabetes benefit, which often has better coverage. The disadvantage is that insurers are increasingly scrutinizing tirzepatide prescriptions. Some plans now require confirmation of a Type 2 diabetes diagnosis via HbA1c lab results before approving Mounjaro. Others impose dose ceilings designed to prevent off-label obesity prescribing through the diabetes channel. Enforcement is uneven, but the trend is toward tighter controls.

Compounded tirzepatide has emerged as a third option. Under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies can produce copies of FDA-approved drugs during recognized drug shortages. Compounded tirzepatide typically costs between $200 and $600 per month depending on the pharmacy, formulation, and dose. The regulatory status depends on the FDA Drug Shortage Database listings, which have fluctuated. Patients considering this route should verify that the pharmacy is a state-licensed 503A pharmacy (requires a valid patient-specific prescription) or an FDA-registered 503B outsourcing facility (subject to cGMP standards and FDA inspection). Quality and potency can vary between compounders, which is a tradeoff against the substantial cost savings.

Supply availability is another practical factor. Mounjaro and Zepbound are manufactured on different production lines and distributed through different supply chains despite containing the same active ingredient. A pharmacy may have one in stock but not the other at a given dose strength. Patients starting either medication should ask their prescriber about contingency plans if their dose becomes temporarily unavailable.

If a patient switches from Mounjaro to Zepbound or vice versa, no dose adjustment, new titration, or washout period is required. The switch is purely administrative. The prescriber writes a new prescription for the other product, and the insurance claim processes through a different benefit category. The medical record should reflect that it is the same medication under a different label.

One forward-looking consideration: Eli Lilly is studying tirzepatide for additional conditions including obstructive sleep apnea, heart failure with preserved ejection fraction, and metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH). New FDA indications could expand which product carries which label claims, potentially shifting insurance coverage decisions and prescribing patterns. The regulatory landscape around this molecule is still evolving.

The Bottom Line

Mounjaro and Zepbound are the same drug made by the same company, delivered in the same device, at the same doses, on the same schedule. The molecule is tirzepatide. The mechanism is dual GLP-1/GIP receptor agonism. The clinical effects are identical at identical doses.

The practical differences are regulatory and financial. Mounjaro is labeled for Type 2 diabetes based on the SURPASS trial program. Zepbound is labeled for chronic weight management based on the SURMOUNT trials (PMID: 35658024). Which one your doctor prescribes depends on your diagnosis, your insurance plan, and which coverage pathway gives you the best chance of affordable, uninterrupted access.

If you have Type 2 diabetes, Mounjaro is the on-label choice and typically the simpler insurance pathway. If weight loss is your primary goal and you do not have diabetes, Zepbound is the product that was specifically tested and approved for that purpose, with SURMOUNT data supporting its use at doses up to 15 mg for average weight loss exceeding 20% of body weight.

People currently on off-label Mounjaro for weight loss and doing well do not necessarily need to switch. But they should understand how their insurance classifies the prescription and whether coverage could be disrupted if the insurer tightens enforcement around on-label prescribing.

The question is not "which drug is better." They are the same drug. The question is which product gives you the most reliable, affordable access to tirzepatide for your specific clinical situation. Start that conversation with your prescriber. They can evaluate your medical profile, check your insurance formulary, and navigate the specific coverage rules that apply to your plan.